Australian vaccines and blood products developer CSL Ltd. said Monday that the U.S. Federal Trade Commission is likely to block its proposed $3.1 billion acquisition of rival Talecris Biotherapeutics Inc.
CSL expects regulatory objection to Talecris bidCourtesy Newsvine - business Mon, 05/25/2009 - 15:35
Australian vaccines and blood products developer CSL Ltd. said Monday that the U.S. Federal Trade Commission is likely to block its proposed $3.1 billion acquisition of rival Talecris Biotherapeutics Inc. Related itemsFor $2 a Star, a Retailer Gets 5-Star Reviews
China prepares for big entry into vaccine market
Reebok to Pay $25 Million Over Toning Shoe Claims
Samsung SCX-4200 3-in-1 True Multifunction Printer
BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
|
Popular by tags WeekMonth |
Post new comment